Cell Genesys And Medarex Announce Encouraging Follow-Up Results From A Phase 1 Combination Therapy Trial For Prostate Cancer

... Cell Genesys, Inc. (Nasdaq: CEGE) and Medarex, Inc. (Nasdaq: MEDX) today announced encouraging follow-up data from the ongoing Phase 1 clinical trial of Cell Genesys' GVAX immunotherapy for prostate cancer, administered in combination with Medarex's fully human anti-CTLA-4 antibody, ipilimumab (MDX-010). Medarex is jointly developing ipilimumab with Bristol-Myers Squibb Company. [click link for full article] ...